The Tough Tech Problem we are solving
At Phare Bio, we’re tackling one of the most urgent and complex challenges in healthcare: antimicrobial resistance (AMR). Superbugs -- bacteria that have evolved to withstand nearly all existing antibiotics -- pose a growing threat to global health, with projections of nearly 40 million lives lost annually by 2050 if new treatments aren’t developed. Despite this looming crisis, antibiotic discovery has stagnated for decades. Most new antibiotics are slight modifications of existing drugs, leaving bacteria to continue evolving to evade them and rendering them ineffective. Traditional antibiotic discovery has been largely abandoned by the pharmaceutical industry due to scientific and economic challenges, leaving an enormous gap between urgent patient needs and drug development. Phare Bio is changing that.
About our solution
Phare Bio is pioneering a new frontier in antibiotic discovery by using generative AI to design entirely new antibiotic candidates from scratch. Our AI-powered drug discovery platform rapidly identifies and optimizes novel compounds with new mechanisms of action -- compounds that would not be discovered through traditional screening methods. By compressing discovery timelines from years to months, we can move promising candidates toward preclinical development faster and with greater precision. Beyond discovery, our hybrid business model -- combining philanthropic and grant funding with sustainable revenue streams, including partnerships, licensing, and spin-out ventures -- ensures that the antibiotics we create are not just breakthroughs in the lab, but treatments that reach the patients who need them most.